Every 10-Q that 10x Genomics, Inc. (TXG) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TXG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TXG filings page.
10x Genomics, Inc. reported Q2 2026 total revenue of $151.0M, down 13% from Q2 2025, mainly because prior-year results included large, non-recurring patent-license settlements. Underlying products and services revenue rose 3% to $149.1M, driven by consumables and services growth, while instrument revenue fell 47%.
Gross margin improved to 74%, helped by lower inventory write-downs, warranty costs and tariff refunds. The company posted a net loss of $17.9M for Q2 and $31.4M for the first half of 2026, versus a small profit a year earlier. Cash and cash equivalents were $502.5M plus $49.5M of marketable securities, with $43.1M of operating cash inflow in the first half.
10x acquired Proteintech Genomics, Inc. for $6.1M in cash, recording $3.7M of developed-technology intangibles and $2.4M of goodwill, and separately capitalized a $12.4M long-term supply agreement. Fair-value contingent consideration tied to the prior Scale Biosciences acquisition was $10.1M at June 30, 2026, with up to $30.0M potentially payable on future milestones. The company also resolved litigation with Takara, while other IP cases continue. Management states that, excluding one-time litigation-related items, it expects 2026 revenues to moderately increase and operating expenses to modestly decrease versus 2025.
10x Genomics, Inc. reported Q1 2026 revenue of $150.8 million, slightly below $154.9 million a year earlier as prior-year license and royalty revenue tied to a Vizgen settlement rolled off. Core products and services revenue rose to $149.9 million, up 9% year over year, driven by 13% growth in consumables.
Gross profit was $106.2 million with gross margin improving to 70% from 68%, helped by lower inventory write-downs and warranty costs, partly offset by lower license revenue. Operating expenses fell 15% to $123.2 million, reflecting lower legal, personnel and marketing costs.
Net loss narrowed to $13.5 million (basic and diluted loss per share $0.10) from $34.4 million. The company generated $26.1 million of operating cash flow and ended the quarter with $539.8 million in cash, cash equivalents and marketable securities, while continuing to fund litigation, integration of the Scale Biosciences acquisition and milestone and lease commitments.
10x Genomics (TXG) reported Q3 2025 results with revenue of $149.0 million and a net loss of $27.5 million. Gross margin was 67%. Products and services revenue fell 2% year over year as instruments declined 37% to $12.0 million, while consumables rose 1% to $127.9 million and services grew 29% to $8.1 million.
Year-to-date, revenue reached $476.8 million, including $45.8 million of license and royalty revenue tied to settlements with Vizgen and Bruker, alongside a $49.9 million gain on settlement. Cash, cash equivalents, and marketable securities totaled $482.1 million as of September 30, 2025.
The company closed the Scale Biosciences asset acquisition with $9.2 million cash and $13.5 million in stock (1,099,992 shares), recorded $22.4 million of contingent consideration at fair value, and expects a $20.0 million payment in Q1 2026. A May 2025 restructuring recorded $6.0 million in charges. Management noted revenues are expected to moderately increase sequentially in Q4 2025 and gross margin may fluctuate with mix and non-recurring items.